Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it will be hosting advisory board meetings at two upcoming urologic community forums to present data from its Phase 2 bladder cancer study.
The Phase 2 clinical study, known as Study 2, provides a study procedure for patients diagnosed with Bacillus Calmette Guerin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS). The study was designed to evaluate Theralase's photodynamic therapy technology.
The company said that the meeting will take place on April 12, during the Canadian Urological Association Bladder Cancer Forum being held in Toronto, Ontario, to provide an update to all Canadian Principal Investigators of the Study 2 interim clinical data and discuss patient enrollment opportunities.
A second advisory board meeting will take place on May 4, during the 2024 American Urology Association meeting in San Antonio, Texas, where an update will be made to all Canadian and US-based Principal Investigators.
The interim clinical data to be presented details the safety and efficacy of Ruvidar-based photodynamic therapy (PDT) for the treatment of BCG-unresponsive NMIBC CIS, Theralase chief scientific officer Dr Arkady Mandel said.
“The current interim Phase II clinical study analysis demonstrates a significant clinical advantage of the Theralase technology in the current treatment landscape and provides potential for a novel, effective and lasting treatment option for these patients,” Mandel said.
“Moving forward, we are continuing to advance new patient recruitment with the goal of completing patient recruitment for our Phase 2 study by year-end.”
Mandel highlighted that patients with BCG-Unresponsive NMIBC CIS have limited treatment options other than bladder removal surgery.